Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Ratios

Tvardi Therapeutics (TVRD) Capital Expenditures (2016 - 2024)

Tvardi Therapeutics' Capital Expenditures history spans 11 years, with the latest figure at $210000.0 for Q2 2024.

On a quarterly basis, Capital Expenditures changed N/A to $210000.0 in Q2 2024 year-over-year; TTM through Dec 2024 was $1.0 million, a 33.29% decrease, with the full-year FY2024 number at $1.0 million, down 55.96% from a year prior.
Capital Expenditures hit $210000.0 in Q2 2024 for Tvardi Therapeutics, down from $836000.0 in the prior quarter.
Over the last five years, Capital Expenditures for TVRD hit a ceiling of $1.6 million in Q4 2023 and a floor of $43000.0 in Q1 2022.
Historically, Capital Expenditures has averaged $564800.0 across 4 years, with a median of $210000.0 in 2024.